Erasca Inc (ERAS) is the lead sponsor of 6 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 5 Phase 1[3].
Trial NCT06346067[5] evaluates Naporafenib in Advanced or Metastatic NRAS-mutant Melanoma with a target enrollment of 78 participants.
ERAS has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].